Business
Esperion Announces Commercial Availability of NEXLIZET™ (bempedoic acid and ezetimibe) Tablets and Ushers in New Era of Oral Combination Medicine for LDL-Cholesterol Lowering
– First-Ever Non-Statin Combination Medicine, Providing 38 Percent Mean LDL-C Lowering – – Esperion Aims to Set New Industry Standard by Pricing NEXLIZET for
About this update from Esperion Therapeutics, Inc.
[{"type":"text","content":"– First-Ever Non-Statin Combination Medicine, Providing 38 Percent Mean LDL-C Lowering – – Esperion Aims to Set New Industry Standard by Pricing NEXLIZET for Patient Affordability and Access with Minimal to No Paperwork Requirements for Health Care Providers –– Launch Date Accelerated by One Month at Health Care Providers Request –\n ANN ARBOR, Mich., June 04, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced today that NEXLIZETTM (bempedoic acid and ezetimibe) tablets, the first approved oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering combination medicine is now available in U.S. pharmacies. NEXLIZET provides significant efficacy with a positive risk-benefit profile and requires minimal to no paperwork for health care providers (HCPs) during this incredibly demanding and unprecedented time when patients start to re-focus on their long-term health needs and underlying conditions. Additionally, NEXLIZET is introduced with broad payer coverage for both eligible insured patients and those with Medicare Part D at an affordable price and co-pay. As the first non-statin LDL-C lowering fixed dose combination medicine ever approved by the FDA, NEXLIZET offers healthcare providers the opportunity to simultaneously use complementary medicines in a single oral tablet with no titration. NEXLIZET is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C. The effect of NEXLIZET on cardiovascular morbidity and mortality has not been determined. NEXLIZET lowered LDL-C by a mean of 38 percent compared to placebo when added on to maximally tolerated statins. Results have been published in The European Journal of Preventive Cardiology. “I am excited to have a newly approved statin add-on combination medicine. “NEXLIZET offers substantial LDL-lowering efficacy with a positive risk-benefit profile. It is a single pill with a single co-pay and is indicated for patients struggling to reach their cholesterol goals despite diet plus maximally-tolerated statin therapy,” said Eliot A. Brinton, MD, FAHA, FNLA, FACE, President of the Utah Lipid Center, past-President of the American Board of Clinical Lipidology and advisor to Esperion. ...